Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ChimeriVax
- Development stage
- Unknown
- Lead developer
- Parent
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
ChimeriVax is a vaccine platform and series of live-attenuated, recombinant vaccines developed using the ChimeriVax technology. This technology utilizes the yellow fever virus (YF) 17D vaccine strain as a vector to deliver the envelope genes (prM and E) of other flaviviruses such as Japanese encephalitis virus (JEV) or West Nile virus (WNV). The resulting vaccines are live, attenuated viral constructs that express protective antigens from target flaviviruses while retaining the safety profile of YF 17D. ChimeriVax-JE is indicated for prevention of Japanese encephalitis and has demonstrated high immunogenicity and durable protection in both adults and children. ChimeriVax-WN02 targets West Nile virus infection and has shown strong immunogenicity in clinical trials. The primary mechanism is induction of neutralizing antibodies against the envelope proteins of target flaviviruses through presentation by a live-attenuated viral vector[1][2][3][4].
- Brand names
- chimerivax-je
- Other names
- chimerivax-wnchimerivax-wn02chimerivax-wn-02chimerivax-wn 02chimerivax technology
02
Targets
E (Tick-borne encephalitis virus envelope protein)
Beyond the preview
Go deeper on ChimeriVax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ChimeriVax.